SCHEMBL5459253

SCHEMBL5459253

NC(=O)c1c(NC(=O)Nc2ccc(I)cc2)sc2c1CCC1(C2)OCCO1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
EPHB4 P54760 1/20 0.51
KCNH2 Q12809 10/20 0.50
TNIK Q9UKE5 1/20 0.47
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 2/20 0.42
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
FLT3 P36888 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447449 0.90 KMT2A (0.53) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5448343 0.90 MEN1 (0.63) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5460583 0.89 FLT3 (0.53) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5451995 0.87 FLT3 (0.51) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5455882 0.87 PTPN1 (0.49) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5451290 0.85 PTPN1 (0.47) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5455249 0.85 KCNH2 (0.50) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5467916 0.84 FLT3 (0.52) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5451443 0.84 MEN1 (0.51) PTPN1MEN1KMT2ANPC1RAB9A
SCHEMBL5449715 0.80 PTPN1 (0.48) PTPN1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 PTPN1 2192/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.